KLAVA

KLAVA is a pioneering pharmaceutical manufacturing company dedicated to revolutionizing the treatment of addictive disorders. With a commitment to improving access to evidence-based care, KLAVA collaborates with leading research institutions to develop innovative solutions that address the challenges of addiction. KLAVA's dedication extends to advancing equitable access to high-quality care for patients affected by substance use disorders.

KLAVA has focused its research efforts on tobacco dependence, resulting in the development of Quitoxil®, a groundbreaking digital therapeutic accessible via smartphone. This program incorporates clinically validated cognitive and behavioral therapies, empowering individuals to reduce or stop tobacco use. Quitoxil® became the first French digital therapeutic for addiction to be distributed in community pharmacies.

KLAVA, located in Boulogne Billancourt, FR, is rapidly establishing itself as a leader in digital therapeutics for addiction medicine. With plans to expand its scope to address other addiction-related conditions, including sugar addiction, KLAVA is poised for continued growth and impact in the healthcare sector. The information will be completed soon with the support of the company’s management.

We invite the manager of KLAVA to create a customized and exclusive company showcase and product listing on our platform.